文献速递外周动脉疾病

股腘动脉病变斑块旋切术的急性期与中期结果

Acute and Mid-Term Results of Atherectomy in Femoropopliteal Lesions.
PubMed 文献 · J Endovasc Ther · 2024-03-28

这项回顾性分析纳入955例股腘动脉病变患者,接受斑块旋切血管准备,2年靶病变血运重建率为34.3%,定向旋切与前置切割旋切术后24个月靶病变血运重建率分别为32.2%和49%,结论认为中期结果满意。

要点

  • 955例股腘动脉病变患者接受斑块旋切,2年靶病变血运重建率为34.3%。
  • 定向旋切术后24个月靶病变血运重建率为32.2%,前置切割旋切术后为49%。
  • 定向旋切术后24个月一期通畅率为40.3%,前置切割旋切术后为26%。

核心结论

  • 在这项回顾性分析中,股腘动脉病变斑块旋切术显示出满意的中期结果。

研究设计与样本

  • 回顾性分析,纳入接受斑块旋切进行血管准备的患者955例(女性37.8%,平均年龄69.7±9.6岁)。
  • 821例(86%)为间歇性跛行,134例(14%)为危及肢体的严重缺血。
  • 644处病变(67.4%)位于自体动脉,145处(15.2%)为支架内再狭窄,166例患者(17.4%)在自体段和支架内段均行斑块旋切。
  • 837例接受定向旋切,118例接受前置切割旋切。
  • 574例手术(60.1%)后续行药物涂层球囊血管成形术,总体临时支架率为20%。

主要发现

  • 记录到154例手术相关不良事件(16.1%),4例并发症(0.4%)需要外科干预。
  • 2年时279例患者(34.3%)需要靶病变血运重建。
  • 定向旋切术后6、12、24个月靶病变血运重建率分别为9%、19.5%、32.2%,前置切割旋切术后分别为14.2%、29.4%、49%。
  • 定向旋切术后6、12、24个月一期通畅率分别为75.9%、57.4%、40.3%,前置切割旋切术后分别为64.9%、44.8%、26%。
  • 随访期间平均踝肱指数和平均Rutherford-Becker分级显著改善(p<0.001),17例需要截肢,其中13例小截肢(1.6%)、4例大截肢(0.5%)。

临床怎么用

  • 作者认为,斑块旋切作为血管准备后联合药物涂层球囊血管成形术似乎有前景,但需要在随机试验中研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The femoropopliteal arteries are commonly affected by atherosclerotic lesions. The use of atherectomy may increase the benefit of definitive therapy, such as drug-coated balloon (DCB) angioplasty. PURPOSE: To analyze the 2-year safety and efficacy of atherectomy in general and stratified by directional atherectomy (DA) and front-cutting atherectomy (FA) for the treatment of atherosclerotic lesions of the femoropopliteal arteries. METHODS: A retrospective analysis was performed including patients who underwent vessel preparation with atherectomy. The primary endpoint was the 2-year incidence of target lesion revascularization (TLR). Secondary endpoints included primary patency, changes in ankle-brachial index (ABI) and Rutherford-Becker class (RBC), and amputation rate up to 2 years. RESULTS: Nine hundred and fifty-five patients (37.8% female; mean age: 69.7±9.6 years) were included in this analysis. Eight hundred and twenty-one patients (86%) were claudicants, 134 patients (14%) had critical limb-threatening ischemia. Six hundred and forty-four lesions (67.4%) were in a native artery and 145 lesions (15.2%) were in-stent restenoses. In 166 patients (17.4%), atherectomy was performed in native and in-stent segments. Eight hundred and thirty-seven patients were treated with DA and 118 patients with FA. Five-hundred and seventy-four procedures (60.1%) were followed by DCB angioplasty, provisional stent rate was 20% overall. One hundred and fifty-four procedure-related adverse events (16.1%) were documented, four complications (0.4%) required surgical intervention. At 2 years, 279 patients (34.3%) required TLR. After DA, TLR rates were 9%, 19.5%, and 32.2% at 6, 12, and 24 months, respectively, and 14.2%, 29.4%, and 49%, at 6, 12, and 24 months after FA. After DA, primary patency rates were 75.9%, 57.4%, and 40.3% at 6, 12, and 24 months, respectively, and 64.9%, 44.8%, and 26%, at 6, 12, and 24 months, respectively, after FA. Mean ABI and mean RBC improved significantly during follow-up (p<0.001), 17 patients required amputation, 13 minor (1.6%) and four major (0.5%). Regression analysis shows that more calcified lesions are more likely to have a TLR. Compared with a vessel diameter of 4 mm or smaller, larger diameters are associated with fewer TLRs. CONCLUSION: In this retrospective analysis, atherectomy of femoropopliteal lesions shows satisfactory mid-term results. CLINICAL TRIAL REGISTRATION: German Clinical Trials Register: DRKS00031245Clinical ImpactThe results of this analysis could influence the daily practice of the interventionalists. A combination of atherectomy as vessel preparation followed by drug coated balloon angioplasty appears to be promising, but would need to be investigated in randomised trials.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Noory E, Böhme T, Steinhauser Y, et al. Acute and Mid-Term Results of Atherectomy in Femoropopliteal Lesions. J Endovasc Ther. 2024. PMID: 38546131. doi:10.1177/15266028241240898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。